Suvorexant: The first orexin receptor antagonist to treat insomnia.
Suvorexant: The first orexin receptor antagonist to treat insomnia.
复制标题
DOI：
10.4103/0976-500x.155496
复制
发表时间：
2015-04
影响因子：
0.2
通讯作者：
Mediratta PK
中科院分区：
文献类型：
--
作者：
Dubey AK;Handu SS;Mediratta PK
原发性失眠症主要用作用于苯二氮卓受体的药物和用于不同合并症的其他几类药物治疗。最近，随着苏沃雷生的批准，一种新的治疗失眠的方法被引入，苏沃雷生是第一种新的食欲素受体拮抗剂。已经发现大脑中的食欲素受体在唤醒和动机的各个方面的调节中起重要作用。迄今为止，通常用于失眠治疗的药物通常与不良反应有关，例如白天嗜睡、健忘症、意识模糊和步态障碍，以及长期使用依赖的风险。由于其独特的作用机制，苏沃雷生未显示出这些不良反应。它似乎也适合作为失眠的长期治疗，因为最小的身体依赖性。这种新药作为一种有效和安全的替代品的可用性是失眠管理的一个重要和受欢迎的发展。
Primary insomnia is mainly treated with drugs acting on benzodiazepine receptors and a few other classes of drugs used for different co-morbidities. A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists. Orexin receptors in the brain have been found to play an important role in the regulation of various aspects of arousal and motivation. The drugs commonly used for insomnia therapy to date, have often been associated with adverse effects, such as, day-time somnolence, amnesia, confusion, and gait disturbance, apart from the risk of dependence on chronic use. Suvorexant has not shown these adverse effects because of its unique mechanism of action. It also appears to be suitable as a chronic therapy for insomnia, because of minimal physical dependence. The availability of this new drug as an effective and safe alternative is an important and welcome development in insomnia management.